[go: up one dir, main page]

UA111933C2 - Піролопіридини як інгібітори кінази - Google Patents

Піролопіридини як інгібітори кінази

Info

Publication number
UA111933C2
UA111933C2 UAA201015012A UAA201015012A UA111933C2 UA 111933 C2 UA111933 C2 UA 111933C2 UA A201015012 A UAA201015012 A UA A201015012A UA A201015012 A UAA201015012 A UA A201015012A UA 111933 C2 UA111933 C2 UA 111933C2
Authority
UA
Ukraine
Prior art keywords
pyrolopyridine
kinase inhibitors
compounds
formula
chk2
Prior art date
Application number
UAA201015012A
Other languages
English (en)
Inventor
Хюроу Івен Ле
Джеймс Ф. Блейк
Індрані У. Ганвордана
Пітер Дж. Мор
Ілай М. Уоллес
Бін Ван
Марк Чікареллі
Майкл ЛАЙОН
Original Assignee
Еррей Біофарма Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40810786&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA111933(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Еррей Біофарма Інк. filed Critical Еррей Біофарма Інк.
Publication of UA111933C2 publication Critical patent/UA111933C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Сполуки Формули І здатні інгібувати СНК1 та/або СНК2. Розкриті способи застосування сполук Формули І та їх стереоізомерів і фармацевтично прийнятних солей для діагностики, попередження або лікуванні таких розладів або супутніх патологічних станів у клітинах ссавців in vitro, in situ та in vivo.(I)
UAA201015012A 2008-05-13 2009-05-13 Піролопіридини як інгібітори кінази UA111933C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5292608P 2008-05-13 2008-05-13
PCT/US2009/043691 WO2009140320A1 (en) 2008-05-13 2009-05-13 Pyrrolopyridines as kinase inhibitors

Publications (1)

Publication Number Publication Date
UA111933C2 true UA111933C2 (uk) 2016-07-11

Family

ID=40810786

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201015012A UA111933C2 (uk) 2008-05-13 2009-05-13 Піролопіридини як інгібітори кінази

Country Status (30)

Country Link
US (6) US8178131B2 (uk)
EP (2) EP2307409B1 (uk)
JP (2) JP5703212B2 (uk)
KR (2) KR101643426B1 (uk)
CN (3) CN104926810B (uk)
AR (1) AR071717A1 (uk)
AU (1) AU2009246402B2 (uk)
BR (1) BRPI0913580B8 (uk)
CA (1) CA2724262C (uk)
CL (1) CL2009001152A1 (uk)
CO (1) CO6321244A2 (uk)
CR (1) CR11803A (uk)
CY (1) CY1116692T1 (uk)
DK (1) DK2307409T3 (uk)
ES (1) ES2552643T3 (uk)
HK (1) HK1219950A1 (uk)
HR (1) HRP20151018T1 (uk)
HU (1) HUE026160T2 (uk)
IL (1) IL209258A (uk)
MX (1) MX2010012449A (uk)
NZ (1) NZ589318A (uk)
PH (1) PH12013501779B1 (uk)
PL (1) PL2307409T3 (uk)
PT (1) PT2307409E (uk)
RS (1) RS54358B1 (uk)
RU (1) RU2517194C2 (uk)
SI (1) SI2307409T1 (uk)
TW (2) TWI458727B (uk)
UA (1) UA111933C2 (uk)
WO (1) WO2009140320A1 (uk)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2394759T3 (es) 2008-01-08 2013-02-05 Array Biopharma, Inc. Pirrolopiridinas como inhibidores de quinasa
US8372842B2 (en) 2008-01-09 2013-02-12 Array Biopharma Inc. Pyrazolopyridines as kinase inhibitors
JP2009256298A (ja) * 2008-03-26 2009-11-05 Sumitomo Chemical Co Ltd ピペリジン−３−イルカーバメート化合物の光学分割方法およびその中間体
CL2009001152A1 (es) 2008-05-13 2009-10-16 Array Biopharma Inc Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
US8481557B2 (en) 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
SG10201900212QA (en) * 2009-04-11 2019-02-27 Array Biopharma Inc Checkpoint kinase 1 inhibitors for potentiating dna damaging agents
TWI466885B (zh) 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
EP2485589A4 (en) * 2009-09-04 2013-02-06 Biogen Idec Inc HETEROARYL-BTK INHIBITORS
MX2013001970A (es) 2010-08-20 2013-08-09 Hutchison Medipharma Ltd Compuestos de pirrolopirimidina y usos de los mismos.
CA2817968C (en) 2010-11-16 2019-03-12 Array Biopharma Inc. Combination of checkpoint kinase 1 inhibitors and wee 1 kinase inhibitors
US8889704B2 (en) 2011-02-25 2014-11-18 Array Biopharma Inc. Triazolopyridine compounds as PIM kinase inhibitors
JP2014516941A (ja) 2011-04-29 2014-07-17 アムジェン インコーポレイテッド Ｐｉｍ阻害剤としての二環式ピリダジン化合物
GB201201566D0 (en) 2012-01-30 2012-03-14 Vernalis R&D Ltd New chemical compounds
NZ702135A (en) 2012-04-23 2016-09-30 Genentech Inc Intermediates and processes for preparing 5-bromo-4-chloro-3-nitro-1h-pyrrolo[2,3-b]pyridine
AU2014293011A1 (en) 2013-07-26 2016-03-17 Race Oncology Ltd. Compositions to improve the therapeutic benefit of bisantrene
MX369174B (es) * 2013-08-22 2019-10-30 Genentech Inc Proceso para la preparación de un compuesto.
WO2015027090A1 (en) * 2013-08-22 2015-02-26 Genentech, Inc. Intermediates and processes for preparing compounds
EP3049415B1 (en) * 2013-09-25 2018-07-04 Vertex Pharmaceuticals Incorporated A selective inhibitor of phosphatidylinositol 3-kinase-gamma
CA2946538A1 (en) 2014-04-04 2015-10-08 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
TW201613919A (en) 2014-07-02 2016-04-16 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
MA41599A (fr) * 2015-02-26 2018-01-02 Array Biopharma Inc Formes cristallines d'un composé pyrrolopyridine
CN107708414B (zh) 2015-06-30 2022-02-25 首尔伟傲世有限公司 适用紫外线发光二极管的捕虫器
TW202510883A (zh) 2015-11-04 2025-03-16 德商默克專利有限公司 使用具有ｂｔｋ抑制活性之嘧啶及吡啶化合物治療癌症之方法
EP3394064A1 (en) * 2015-12-22 2018-10-31 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-mll interaction
PT3468966T (pt) 2016-06-10 2020-11-10 Vitae Pharmaceuticals Llc Inibidores da interação menina-mll
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
CN112839648B (zh) 2018-06-07 2025-04-04 达萨玛治疗公司 Sarm1抑制剂
MA53095A (fr) 2018-07-03 2021-05-12 Ifm Due Inc Composés et compositions pour traiter des états pathologiques associés à une activité de sting
CN108912032A (zh) * 2018-08-13 2018-11-30 南通大学 一种（3s，4r）-4-甲基吡咯烷-3-基氨基甲醇叔丁酯盐酸盐的化学合成方法
CN109053526A (zh) * 2018-08-13 2018-12-21 南通大学 一种（3r，4s）-4-甲基吡咯烷-3-基氨基甲酸叔丁酯盐酸盐的化学合成方法
JP7212781B2 (ja) 2018-12-19 2023-01-25 ディスアーム セラピューティクス， インコーポレイテッド 神経保護剤と組み合わせたｓａｒｍ１の阻害剤
WO2020150417A2 (en) 2019-01-17 2020-07-23 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
JP2023540673A (ja) 2020-07-15 2023-09-26 アイエフエム デュー インコーポレイテッド Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
WO2022150585A1 (en) 2021-01-08 2022-07-14 Ifm Due, Inc. Heterobicyclic compounds having an urea or analogue and their compositions for treating conditions associated with sting activity
BR112023023463A2 (pt) 2021-05-14 2024-01-30 Syndax Pharmaceuticals Inc Inibidores da interação menin-mll
IL310724A (en) 2021-08-10 2024-04-01 Ifm Due Inc COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH STING ACTIVITY
CN119798252A (zh) * 2023-10-09 2025-04-11 中国石油化工股份有限公司 一种制备n邻位-酰基取代的含氮杂环化合物及其缩胺合铁(ii)配合物的方法
WO2025260014A1 (en) * 2024-06-14 2025-12-18 Tenvie Therapeutics, Inc. Compounds, compositions, and methods

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09503783A (ja) * 1993-10-14 1997-04-15 アボツト・ラボラトリーズ キノリジノン型化合物
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
CA2399791A1 (en) 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
CA2398446A1 (en) 2000-04-18 2001-10-25 Agouron Pharmaceuticals, Inc. Pyrazoles for inhibiting protein kinases
WO2003022214A2 (en) 2001-09-06 2003-03-20 Millennium Pharmaceuticals, Inc. Piperazine and homopiperazine compounds
WO2003028724A1 (en) * 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
US6797825B2 (en) * 2001-12-13 2004-09-28 Abbott Laboratories Protein kinase inhibitors
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
EP1537106A1 (en) 2002-08-07 2005-06-08 Mitsubishi Pharma Corporation Dihydropyrazolopyridine compounds
US20050256157A1 (en) * 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
TWI270549B (en) 2002-12-26 2007-01-11 Taisho Pharmaceutical Co Ltd Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with cyclic amino group
WO2004081008A1 (en) 2003-03-14 2004-09-23 Astrazeneca Ab Novel fused triazolones and the uses thereof
GB0308208D0 (en) * 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
GB0330043D0 (en) * 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
GB0330042D0 (en) * 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them
AR049333A1 (es) * 2004-04-02 2006-07-19 Vertex Pharma Azaindoles inhibidores de proteinquinasas rock y otras proteinas quinasas. composiciones farmaceuticas.
AU2005244745B2 (en) * 2004-04-13 2012-05-03 Synta Pharmaceuticals Corp. Disalt inhibitors of IL-12 production
GB0409080D0 (en) 2004-04-23 2004-05-26 Biofocus Discovery Ltd Compounds which interact with protein kinases
JP2007161585A (ja) 2004-06-25 2007-06-28 Taisho Pharmaceut Co Ltd 環状アミノ基で置換されているピロロピリミジン及びピロロピリジン誘導体
UY29177A1 (es) * 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
BRPI0608659A2 (pt) 2005-04-06 2010-11-30 Astrazeneca Ab composto, métodos para limitar a proliferação celular, de tratamento de um ser humano ou animal sofrendo de uma doença, e de tratamento de profilaxia do cáncer, para tratar cáncer, de tratamento de infecções associadas com cáncer, e de profilaxia de infecções associadas com cáncer, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, métodos para inibir chk1 cinase, e um pak cinase, e para limitar a tumorigênese em um ser humano ou animal, e, processo para a preparação de um composto ou um sal farmaceuticamente aceitável do mesmo
WO2006127587A1 (en) 2005-05-20 2006-11-30 Vertex Pharmaceuticals Incorporated Pyrrolopyridines useful as inhibitors of protein kinase
RU2376300C1 (ru) * 2005-08-30 2009-12-20 Асахи Касеи Фарма Корпорэйшн Сульфонамидное соединение
BRPI0617150A2 (pt) 2005-10-06 2011-07-12 Schering Corp pirazolopirimidinas como inibidores de protéina cinase
CA2627623C (en) * 2005-10-06 2014-04-22 Schering Corporation Methods for inhibiting protein kinases
EP2343298B9 (en) 2005-12-13 2020-05-06 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
TW200738709A (en) 2006-01-19 2007-10-16 Osi Pharm Inc Fused heterobicyclic kinase inhibitors
DE102006005180A1 (de) 2006-02-06 2007-08-09 Merck Patent Gmbh Indazol-heteroaryl-derivate
DE102006005179A1 (de) 2006-02-06 2007-08-09 Merck Patent Gmbh Aminoindazolderivate
JP5606734B2 (ja) * 2006-04-25 2014-10-15 アステックス、セラピューティックス、リミテッド 医薬化合物
EP2037931A2 (en) 2006-04-25 2009-03-25 Astex Therapeutics Limited Pharmaceutical combinations of pk inhibitors and other active agents
WO2007125315A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Pharmaceutical compounds
WO2008012635A2 (en) * 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
WO2008075007A1 (en) 2006-12-21 2008-06-26 Cancer Research Technology Limited Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents
AU2008221263B2 (en) 2007-03-01 2012-02-23 Novartis Ag Pim kinase inhibitors and methods of their use
WO2009004329A1 (en) 2007-07-02 2009-01-08 Cancer Research Technology Limited 9h-pyrimido[4,5-b]indoles, 9h-pyrido[4',3':4,5]pyrrolo[2,3-d]pyridines, and 9h-1,3,6,9-tetraaza-fluorenes as chk1 kinase function inhibitors
PE20091195A1 (es) 2007-11-07 2009-08-06 Schering Corp Nuevos moduladores de los puntos de control del ciclo celular y su uso en combinacion con inhibidores de quinasa de punto de control
ES2394759T3 (es) * 2008-01-08 2013-02-05 Array Biopharma, Inc. Pirrolopiridinas como inhibidores de quinasa
US8372842B2 (en) * 2008-01-09 2013-02-12 Array Biopharma Inc. Pyrazolopyridines as kinase inhibitors
CL2009001152A1 (es) * 2008-05-13 2009-10-16 Array Biopharma Inc Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
US8481557B2 (en) * 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
US20140221370A1 (en) 2010-07-09 2014-08-07 Array Biopharma Inc. Pyrrolopyridines as kinase inhibitors
CA2817968C (en) 2010-11-16 2019-03-12 Array Biopharma Inc. Combination of checkpoint kinase 1 inhibitors and wee 1 kinase inhibitors

Also Published As

Publication number Publication date
KR20140093266A (ko) 2014-07-25
CN102089307B (zh) 2015-07-01
US8178131B2 (en) 2012-05-15
PT2307409E (pt) 2015-11-04
IL209258A0 (en) 2011-01-31
HK1219950A1 (en) 2017-04-21
CA2724262C (en) 2017-08-15
KR101643426B1 (ko) 2016-07-27
CN104926810A (zh) 2015-09-23
SI2307409T1 (sl) 2015-11-30
US9969727B2 (en) 2018-05-15
TWI554512B (zh) 2016-10-21
BRPI0913580A2 (pt) 2015-10-20
HRP20151018T1 (hr) 2015-10-23
ES2552643T3 (es) 2015-12-01
TW201002707A (en) 2010-01-16
US8758830B2 (en) 2014-06-24
US20160368916A1 (en) 2016-12-22
CL2009001152A1 (es) 2009-10-16
US20140243520A1 (en) 2014-08-28
RS54358B1 (sr) 2016-04-28
DK2307409T3 (en) 2015-09-21
EP2307409A1 (en) 2011-04-13
MX2010012449A (es) 2011-05-25
US8981085B2 (en) 2015-03-17
KR101657856B1 (ko) 2016-09-19
US20130045286A1 (en) 2013-02-21
NZ589318A (en) 2011-06-30
CN109942575A (zh) 2019-06-28
US20150322061A1 (en) 2015-11-12
AU2009246402B2 (en) 2013-05-23
TWI458727B (zh) 2014-11-01
IL209258A (en) 2017-01-31
KR20110008102A (ko) 2011-01-25
PL2307409T3 (pl) 2016-01-29
CY1116692T1 (el) 2017-03-15
TW201529573A (zh) 2015-08-01
CN104926810B (zh) 2019-02-19
BRPI0913580B8 (pt) 2021-05-25
US20110070317A1 (en) 2011-03-24
CO6321244A2 (es) 2011-09-20
RU2010150786A (ru) 2012-06-20
AR071717A1 (es) 2010-07-07
EP2990407A1 (en) 2016-03-02
JP2015098482A (ja) 2015-05-28
US9365568B2 (en) 2016-06-14
HUE026160T2 (en) 2016-05-30
EP2990407B1 (en) 2019-10-16
WO2009140320A1 (en) 2009-11-19
PH12013501779B1 (en) 2019-02-13
US20140100369A1 (en) 2014-04-10
PH12013501779A1 (en) 2014-08-27
CR11803A (es) 2011-02-11
RU2517194C2 (ru) 2014-05-27
US8545897B2 (en) 2013-10-01
JP2011520896A (ja) 2011-07-21
HK1152035A1 (en) 2012-02-17
CN102089307A (zh) 2011-06-08
AU2009246402A1 (en) 2009-11-19
CA2724262A1 (en) 2009-11-19
JP5703212B2 (ja) 2015-04-15
EP2307409B1 (en) 2015-08-12
BRPI0913580B1 (pt) 2020-03-10

Similar Documents

Publication Publication Date Title
UA111933C2 (uk) Піролопіридини як інгібітори кінази
SG178899A1 (en) Raf inhibitor compounds and methods of use thereof
WO2009111278A3 (en) Raf inhibitor compounds and methods of use thereof
SG178900A1 (en) Raf inhibitor compounds and methods of use thereof
UA111756C2 (uk) Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
MA32272B1 (fr) Inhibiteurs de raf de pyrazole [3,4-b]pyridine
UA116774C2 (uk) Інгібітори серин/треонінкінази
MX2014005282A (es) Compuestos de 8-fluoroftalazin-1 (2h) -ona.
MX2014014828A (es) Compuestos de 5-azaindazol y metodos de uso.
PH12014500966A1 (en) Alkylated piperazine compounds as inhibitors of btk activity
MX2011009167A (es) Combinaciones de compuestos inhibidores de fosfoinositida 3-cinasa y agentes quimioterapeuticos para el tratamiento contra neoplasia hemotopoyeticas malignas.
WO2008028141A3 (en) Raf inhibitor compounds and methods of use thereof
EA201290957A1 (ru) Пиразол-4-илгетероциклилкарбоксамидные соединения и способы их применения
MX338504B (es) Combinaciones de compuestos inhibidores de fosfoinosituro 3-cinasa y agentes quimioterapeuticos, y metodos de uso.
MX2014005285A (es) Compuestos biciclicos de piperazina.
PH12013502369A1 (en) Diazacarbazoles and methods of use
MY160349A (en) Pyridone and aza-pyridone compounds and methods of use
TW200800996A (en) Heterobicyclic pyrazole compounds and methods of use
SG178986A1 (en) 4-substituted pyridin-3-yl-carboxamide compounds and methods of use
WO2008063202A3 (en) Heterobicyclic thiophene compounds for the treatment of cancer
TW200639163A (en) RAF inhibitor compounds and methods
MX340013B (es) Compuestos de benzoxazepina selectivos para fosfatidilinositol 3-cinasa (pi3k) p110 delta y metodos de uso.
WO2007127175A3 (en) Pharmaceutical compounds
EA201190158A1 (ru) Производные бензофуранила для применения в качестве ингибиторов глюкокиназы
MX2012006822A (es) 1,7-diazacarbazoles y metodos de uso.